Healthcare >> CEO Interviews >> January 22, 2001
KENNETH J. KELLEY is Founder, President and Chief Executive Officer,
Chairman of the Board of IntraBiotics Pharmceuticals, Inc. Mr. Kelley is
an entrepreneur, former venture capitalist and molecular biologist.
Prior to founding IntraBiotics in 1994, he co-founded Calydon, a
biotechnology company focused on prostate cancer where he remains a
director. Mr. Kelley was a Senior Associate at Institutional Venture
Partners (IVP) from 1988 to 1993. He invested with the IVP general
partners more than $40 million in 16 life science start-up companies,
including 13 that are now publicly traded companies. He also served as
Chief Operating Officer for CV Therapeutics, a cardiovascular
biotechnology company, in its first year of operations. Mr. Kelley has
also held positions at McKinsey & Company, an international consulting
firm, and at Integrated Genetics (now Genzyme, Inc.). He holds an MBA
degree from Stanford University and a BA degree in Biochemical Sciences
from Harvard University. Profile
of your company?
Mr. Kelley: The company was founded in January 1994, so we're about to
mark our 7th anniversary of
